Skip to main content
VaccineWatch
VaccinesSymptomsStatesAnalysisToolsDashboardCompare

VaccineWatch

Transparent access to VAERS data for informed decision-making. We present the data as-is, with appropriate context and disclaimers.

Explore Data

  • Vaccines
  • Symptoms
  • Manufacturers
  • States
  • Dashboard
  • Compare Tool
  • Search

Deep Dives

  • The Denominator Problem
  • Onset Timing
  • Lot Number Analysis
  • COVID Impact
  • Myocarditis
  • Death Reports
  • Interactive Tools
  • Reporting Rate Calculator
  • Signal Detection
  • All 23 Articles →

Resources

  • About
  • Methodology
  • FAQ
  • Glossary
  • Side Effects Guide
  • Vaccine Schedule
  • Vaccine Safety
  • Safety Timeline
  • Adverse Events
  • Is VAERS Reliable?
  • Myocarditis
  • Guillain-Barré
  • Allergic Reactions
  • Report an Event
  • Disclaimer
  • VAERS Official Site ↗

Sister Sites

  • OpenMedicaid
  • OpenFeds
  • OpenImmigration
  • OpenCrime
  • OpenSubsidies
  • OpenSpending
  • OpenMedicare
  • OpenLobby
  • WarCosts
  • OpenPrescriber
  • GiveScope
  • TheDataProject.ai

Data source: VAERS (Vaccine Adverse Event Reporting System)

Data through 2026 · Updated quarterly

Built by TheDataProject.ai · © 2026 VaccineWatch

Important: VAERS accepts reports of adverse events following vaccination. For any given report, there is no certainty that the reported event was caused by the vaccine. Reports may contain information that is incomplete, inaccurate, coincidental, or unverifiable. Most reports to VAERS are voluntary, which means they are subject to biases. This data cannot be used to determine if vaccines cause or contribute to adverse events.

⚠️

Important: VAERS reports alone cannot determine if a vaccine caused an adverse event. Reports may contain incomplete, inaccurate, or unverified information. Correlation does not equal causation.

  1. Home
  2. Vaccines
  3. COVID-19 Bivalent (Moderna)
  4. Pruritus genital
COVID-19 Bivalent (Moderna)×Pruritus genital

Pruritus genital Reports for COVID-19 Bivalent (Moderna)

#2099 most reported symptom for this vaccine

3
Reports
0
Deaths
0
Hospitalizations
0
Mortality Rate
%
0
Hosp. Rate
%

Pruritus genital and COVID-19 Bivalent (Moderna)

Pruritus genital has been reported 3 times in association with COVID-19 Bivalent (Moderna) vaccination in VAERS. This represents 0.0% of all 42,946 reports for this vaccine.

Among these reports, 0 mentioned death (0.00%) and 0 involved hospitalization (0.0%).

Pruritus genital is the #2099 most frequently reported symptom for COVID-19 Bivalent (Moderna) out of 2434 total symptoms.

Disclaimer: VAERS reports describe events that occurred after vaccination but do not establish that the vaccine caused the event. Many reported symptoms may be coincidental or related to underlying conditions.

What This Means

Seeing 3 reports of Pruritus genital after COVID-19 Bivalent (Moderna) vaccination may seem alarming, but context is critical.

The mortality rate among these reports is very low at 0.00%, suggesting most cases are non-fatal.

Important Context

•Association, not causation: These reports show Pruritus genital occurred after vaccination, not that the vaccine caused it.
•Background rates: Pruritus genital may occur naturally at baseline rates in the population, unrelated to vaccination.
•Anyone can report: VAERS accepts reports from anyone — patients, parents, healthcare providers — without requiring medical verification.
•Denominator missing: VAERS counts reports, not rates per dose. Without knowing how many doses were given, raw counts can be misleading. Learn more →

Similarly Ranked Symptoms

Postictal state3 reportsBlood pressure immeasurable3 reportsSkin plaque3 reportsOphthalmological examination normal3 reports

Quick Facts

Reports:3
Deaths:0
Hospitalizations:0
% of Vaccine:0.0%
Rank:#2099 of 2434

Related Pages

COVID-19 Bivalent (Moderna) OverviewPruritus genital (All Vaccines)Why Raw Numbers MisleadTop Symptoms Analysis

Data Source

This data comes from the Vaccine Adverse Event Reporting System (VAERS), jointly managed by CDC and FDA.